Predictive factors for complete recovery of post-thrombotic syndrome 6 months after venous recanalization
- PMID: 40653089
- PMCID: PMC12358624
- DOI: 10.1016/j.jvsv.2025.102287
Predictive factors for complete recovery of post-thrombotic syndrome 6 months after venous recanalization
Abstract
Objective: Endovascular recanalization is considered for severely symptomatic patients with post-thrombotic syndrome (PTS) to alleviate symptoms. However, data on complete recovery and its predictors remain limited. This study aimed to assess persistent PTS 6 months after venous recanalization and identify predictive factors.
Design: Single-center retrospective outcome-oriented cohort study.
Methods: We reviewed electronic medical records of patients referred for endovascular venous recanalization between January 1, 2015, and September 30, 2019. Inclusion criteria were PTS defined by a Villalta score of ≥5 or a leg ulcer ≥6 months after a deep vein thrombosis episode. Complete PTS recovery was defined as a Villalta score of <5.
Results: Sixty-seven patients (median age, 40 years; interquartile range, 32-51 years; 78% women; 18% obese) were included. The initial Villalta score was 10 (interquartile range, 7-14). At 6 months, primary and secondary patency rates were 75% and 81%, respectively. Complete recovery was observed in 67% of patients. Multivariate analysis identified the initial Villalta score (odds ratio, 1.36; 95% confidence interval, 1.12-1.65; P = .002) and femoral vein obstruction (odds ratio, 3.79; 95% confidence interval, 1.06-13.61; P = .041) as predictors of persistent PTS, whereas long-term anticoagulation was not significant.
Conclusions: Endovascular recanalization achieved PTS resolution in two-thirds of patients at 6 months, particularly in those with a low initial Villalta score and no femoral vein obstruction. A risk score incorporating these factors may aid clinicians in patient counseling regarding the expected benefits of the procedure.
Keywords: Chronic venous thrombotic obstruction; Deep venous thrombosis; Post-thrombotic syndrome; Prediction; Stenting.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures L.K., N.G., and T.M. acknowledge the following without any relation with the current manuscript. L.K. reports receiving honoraria from Bristol-Myers Squibb, Viatris, and Pfizer SAS and receiving nonfinancial support from Bristol-Myers Squibb, Viatris, Pfizer SAS, Leo Pharma, and Sanofi. N.G. discloses consulting fees or travel awards by Bayer, Bristol-Myers Squibb/Pfizer, and LEO-Pharma. T.M. reports receiving honoraria from Bayer Healthcare SAS and Incyte Biosciences France and receiving nonfinancial support from Abbott France, Alexion Pharma France, Amgen SAS, Bayer Healthcare SAS, Boehringer Ingelheim France, Bristol-Myers Squibb, ICOMED, Incyte Biosciences France, MSD France, and Pfizer SAS.
Figures
References
-
- Kahn S.R., Comerota A.J., Cushman M., et al. American Heart Association Council on Peripheral Vascular Disease Council on clinical cardiology, and council on cardiovascular and stroke nursing, the postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014;130:1636–1661. doi: 10.1161/CIR.0000000000000130. - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
